Insider Selling: Dyadic International (NASDAQ:DYAI) Major Shareholder Sells $64,006.20 in Stock

Dyadic International Inc. (NASDAQ:DYAI) major shareholder Francisco Trust Under Agreemen sold 26,340 shares of the stock in a transaction dated Thursday, June 6th. The shares were sold at an average price of $2.43, for a total transaction of $64,006.20. Following the sale, the insider directly owned 3,522,188 shares in the company, valued at $8,558,916.84. This trade represents a 0.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Dyadic International Stock Down 6.0%

Dyadic International stock opened at $1.00 on Thursday. Dyadic International Inc. has a 12 month low of $0.65 and a 12 month high of $1.35. The stock has a fifty day simple moving average of $0.78 and a two-hundred day simple moving average of $0.83. The company has a current ratio of 2.42, a quick ratio of 2.42 and a debt-to-equity ratio of 4.08. The firm has a market cap of $36.33 million, a price-to-earnings ratio of -4.33 and a beta of 1.15.

Dyadic International (NASDAQ:DYAI) last issued its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). Dyadic International had a negative net margin of 192.40% and a negative return on equity of 1,005.45%. The company had revenue of $1.11 million for the quarter, compared to the consensus estimate of $0.90 million. Equities analysts predict that Dyadic International Inc. will post 0.13 EPS for the current fiscal year.

Institutional Trading of Dyadic International

Several hedge funds and other institutional investors have recently bought and sold shares of DYAI. Bank of America Corp DE grew its holdings in Dyadic International by 16,146.7% during the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 26,965 shares during the last quarter. Marathon Capital Management purchased a new stake in Dyadic International in the 3rd quarter worth about $41,000. Landscape Capital Management L.L.C. bought a new stake in Dyadic International in the third quarter worth about $190,000. Geode Capital Management LLC lifted its stake in Dyadic International by 13.7% in the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after purchasing an additional 36,266 shares during the last quarter. Finally, Apis Capital Advisors LLC purchased a new position in shares of Dyadic International during the third quarter valued at approximately $1,817,000. Hedge funds and other institutional investors own 27.95% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Dyadic International in a research note on Wednesday, June 24th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $3.00.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.